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Background: The impact of dairy intake on cardiometabolic risk factors associated with metabolic syndrome (MetS)
needs further research.
Objective: To investigate the impact of milk consumption on a wide array of cardiometabolic risk factors
associated with MetS (blood lipids, cholesterol homeostasis, glucose homeostasis, systemic inflammation, blood
pressure, endothelial function) in postmenopausal women with abdominal obesity.
Methods: In this randomized, crossover study, 27 women with abdominal obesity consumed two 6-week diets
based on the National Cholesterol Education Program (NCEP), one with 3.2 servings/d of 2% fat milk per 2000 kcal
(MILK) and one without milk or other dairy (NCEP). The macronutrient composition of both diets was comparable
(55% carbohydrates, 15% proteins, 30% fat and 10% saturated fat).
Results: The MILK diet had no significant effect on LDL-C, triglycerides, LDL size, CRP and cell adhesion molecule
concentrations and on indicators of insulin sensitivity. The MILK diet reduced HDL-C, adiponectin, endothelin and
fasting glucose levels as well blood pressure (all P≤ 0.01), but those changes were comparable to those seen with the
NCEP milk-free diet (all between-diet P≥ 0.07). Finally, the MILK diet was associated with lower VLDL apolipoprotein
B fractional catabolic rate (−13.4%; P = 0.04) and plasma sterol concentrations (−12.0%; P = 0.04) compared with the
control NCEP milk-free diet.
Conclusions: These data suggest that short-term consumption of low fat milk in the context of a prudent NCEP diet
has no favorable nor deleterious effect on cardiometabolic risk factors associated with MetS in postmenopausal women
with abdominal obesity.
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Postmenopausal womenBackground
A significant proportion of CVD events in industrialized
countries is attributable to the presence of a cluster of
cardiometabolic perturbations associated with metabolic
syndrome (MetS) [1]. This syndrome encompasses abdom-
inal obesity and dysregulations of glucose and insulin me-
tabolism along with hypertension, impaired endothelial
function [2], inflammation, and a typical dyslipidemic* Correspondence: benoit.lamarche@inaf.ulaval.ca
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article, unless otherwise stated.state that includes elevated plasma triglycerides (TG)
concentrations, low HDL-cholesterol (C) concentrations
and small dense LDL particles [3]. The dyslipidemic state
seen in MetS is caused in part by increased secretion of
VLDL apolipoprotein (apo) B particles and by an en-
hanced HDL apoA-I clearance [4]. Recent studies have
suggested that MetS may also be associated with a per-
turbed cholesterol homeostasis characterized by increased
endogenous cholesterol synthesis and decreased choles-
terol absorption [5]. MetS in various populations has been
shown to be quite prevalent, with values ranging from 8%
to 46% depending on country, gender [6] and age [7]. TheCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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pausal women [8].
Diet is considered to be a key etiological determinant of
MetS [9-11]. Accordingly, data from several prospective
cohort studies have shown that dairy and milk consump-
tion was associated with a lower prevalence of MetS
[12,13]. Meta-analyses of cohort studies have also shown
that milk intake was associated with a reduced risk of
hypertension [14,15], but not with type 2 diabetes risk
[16-18]. On the other hand, data from randomized clinical
trials having assessed the impact of milk consumption on
cardiometabolic risk factors are mixed and not fully
consistent with data from epidemiological studies [19-24].
In order to better understand the effect of milk con-
sumption on cardiometabolic health, we have investigated
in a randomized crossover controlled study the impact of
milk consumption on a large array of cardiometabolic fea-
tures associated with MetS, namely blood lipids, choles-
terol and glucose homeostasis, blood pressure, endothelial
function, inflammation, VLDL apoB and HDL apoA-1
kinetics in postmenopausal women with abdominal
obesity. We hypothesized that milk consumption as
part of a prudent diet has significant beneficial effects




Twenty-nine overweight postmenopausal women in
good health were recruited in the Quebec City Metro-
politan area. Twenty-seven of these women completed
the study. Two subjects have dropped out for personal
reasons that were unrelated to the dietary intervention.
All participants were Caucasian of French ancestry ex-
cept two women with South Asian and Chilean ancestries
respectively. Subjects were initially screened on the basis
of a complete physical examination and medical history.
Women eligible for the study had to be less than 70 years
of age, non-smokers, with absence of menses > 12 months,
follicle-stimulating hormone (FSH) > 35 IU/ml, and waist
circumference ≥ 88 cm. Women with a previous history of
CVD, type 2 diabetes, monogenic dyslipidemia, using
lipid-lowering medications, with endocrine disorders or
on hormonal replacement therapy were not eligible.
Exclusion criteria also included aversion for milk, par-
ticular nutritional habits such as limited or absence of
dietary animal proteins, excessive alcohol consumption
(>2 drinks/day) or significant weight change in the
6 months that preceded the experiment. There was no
inclusion/exclusion criteria related to dairy intake as
part of participants’ usual diet. MetS was defined based
on the NCEP-ATP III definition for women [25], i.e.
meeting 3 or more of the 5 following criteria: waist
circumference > 88 cm, plasma triglycerides > 1.7 mmol/L,plasma HDL-C <1.3 mmol/L, blood pressure ≥130/85 mm
Hg and fasting glucose >6.1 mmol/L. The study protocol
was explained to the participants, who gave their writ-
ten informed consent. The protocol was approved
by the Clinical Research Ethics Committee of Laval
University. This trial was registered at clinicaltrials.
gov as NCT01163773.
Experimental design and dietary intervention
A randomized crossover design was used to investigate
the impact of milk consumption on cardiometabolic
features of MetS. The protocol first included a 4-week
stabilization run-in period during which participants were
instructed to comply to the NCEP Phase 1 prudent dietary
recommendations [25]. Participants then consumed in
random order a diet from which approximately 20% of
calories came from partly skimmed milk (2% fat) and a
control NCEP milk-free diet. Both pre-defined regimens
were consumed under isocaloric conditions for periods of
6 weeks each separated by a wash-out period of 6 to
8 weeks, during which the NCEP Phase 1 dietary guide-
lines were reinforced. During the run-in and washout
periods, women were asked to maintain their weight con-
stant. Also, dairy products consumption was not formally
excluded. In that context, women were consuming sub-
stantially more milk during the MILK phase (3.2 serv/d)
and substantially less milk during the NCEP control phase
(0 serv/d) than during the run-in (1.4 serv/d) and wash-
out periods (1.3 serv/d).
All meals were provided to participants during the diet-
ary controlled phases of the study. Lunch was consumed
at the Clinical Investigation Unit every weekday under the
monitoring of registered dieticians while breakfast and
dinner on weekdays and all meals on weekends were
packed and consumed at home. Subjects were asked to
eat all the food and only the food that was provided to
them. They were provided with a daily reminder sheet on
which they were required to check all food items con-
sumed and to report any deviation from the diet, as well
as any illness or use of medication. Analysis of these
checklists indicated that compliance to the experimental
diets was excellent (>98%).
Usual energy and dietary intakes were assessed at
screening using a validated self-administered food fre-
quency questionnaire (FFQ) [26]. Participants began the
study at a pre-defined energy level that was closest to the
mean between their energy intake estimated by the FFQ
and by the Harris-Benedict formula. Weight was moni-
tored every weekday before lunch, and the energy level
was adjusted if body weight had fluctuated from baseline
by more than 1.0 kg. Consumption of alcohol as well as of
vitamin supplements and natural health products during
each experimental period was forbidden. Consumption of
caffeinated beverages such as diet soft drinks (12-oz or
Drouin-Chartier et al. Nutrition Journal 2015, 14:12 Page 3 of 10
http://www.nutritionj.com/content/14/1/12355 ml), coffee and tea (8-oz or 237 ml) was limited to a
maximum of 2 drinks/d.
Participants and staff could not be blinded to the experi-
mental procedures due to the inclusion of milk in the
MILK phase. However, all laboratory analyses were under-
taken in a blinded fashion. Participants were asked to
maintain their usual levels of physical activity throughout
the study. Physical activity level was assessed during the
study using a 3-days (2 weekdays and 1 weekend day)
physical activity questionnaire (data not shown).
Composition of diets
The 2 experimental regimens were formulated so that
the percentage of daily calories from fat (~29%), satu-
rated fat (~10%), carbohydrates (~55%) and proteins
(~17%) (Table 1) complied with the dietary recommen-
dations from the NCEP for primary prevention of CVD
[25]. The seven-day cyclic menus in the MILK diet and
the NCEP control diet were identical in terms of foods,
calories and macronutrient composition, with the excep-
tion that milk and any other forms of dairy products
were formally excluded from the NCEP control diet. An
example of a one-day menu is presented in the Additional
file 1: Table S1. Differences in macronutrient composition
attributable to milk in the MILK diet were compensated,
in the milk-free NCEP diet, by adding animal proteinTable 1 Composition of the experimental diets as well as
baseline dietary habits of participants
Diets
Usual NCEP MILK
Energy (kcal) 2113.0 ± 677.9 2306.6 ± 210.5a 2319.9 ± 266.6a
Protein (%kcal) 17.6 ± 2.6 17.4 17.3
Carbohydrates (%kcal) 50.2 ± 5.8 55.5a 55.6b
Fat (%kcal) 33.2 ± 5.2 28.9a 29.6b
Saturated (%kcal) 12.0 ± 2.8 9.4a 9.8b
Monounsaturated
(%kcal)
13.5 ± 2.5 12.0a 12.6
Polyunsaturated
(%kcal)
5.2 ± 1.3 4.8 4.9
Cholesterol (mg/d) 266.1 ± 90.8 319.8 ± 29.2a 322.2 ± 37.0a
Total fibers (g/d) 21.3 ± 6.8 25.8 ± 2.4a 25.8 ± 3.0a
Calcium (mg/d) 1167.3 ± 500.8 445.9 ± 40.7a 1550.4 ± 178.2a,b
Vitamin D (mcg/d) 6.6 ± 3.0 3.7 ± 0.3a 12.2 ± 1.4a,b
Alcohol (g/d) 2.7 ± 3.1 0a 0a
Glycemic Index ND 54.2 51.3
Glycemic Load ND 146.7 135.7
Values are shown as mean ± SD. ND: not determined.
aSignificantly different from the usual diet (P < 0.05).
bSignificantly different from the NCEP diet (P < 0.05).
Differences between diets were tested by the MIXED procedure for
repeated measurements.(mostly red meat and white egg power), carbohydrates
(mostly fruits) and lipids (mostly lard). We felt it was more
appropriate to use animal rather than vegetable sources of
saturated fat to match the two diets. Cholesterol intake
when expressed per 2000 kcal intake was very similar
between usual diet and the two experimental regimens
(260–280 mg/2000 kcal, not shown). Overall, this allowed
us to assess the impact of milk consumption per se and
not in comparison with replacement control foods. On the
other hand, between-diet differences in micronutrient
intake attributable to milk (calcium, vitamin D) were not
adjusted for. The glycemic index and glycemic load of the
NCEP and MILK diets were calculated using existing
databases [27,28]. The breakfast meal represented ap-
proximately 20% of the daily energy intake whereas
lunch and dinner each provided 40% of daily energy in-
take. As indicated above, 20% of daily calories came
from 2% fat milk, corresponding to 3.2 servings of milk
per 2000 kcal.Risk factor assessment
Most cardiometabolic outcomes were measured at the
beginning and at the end of each dietary phase except for
glucose tolerance, VLDL apoB and apoA-I kinetics and
surrogates of cholesterol homeostasis and of endothelial
function, which were assessed only at the end of each
intervention period. Waist circumference was measured
midway between the lowest rib and the iliac crest using a
standard tape measure [29]. Blood pressure (BP) was mea-
sured after a 5 min rest in the sitting position. It was
measured on the right arm using a standard mercury
sphygmomanometer and was computed as the mean of
3 readings each separated by a 3 min interval. The
Korotkoff sound V was taken as the diastolic blood
pressure. Mean arterial blood pressure (MAP) was
calculated as the sum of diastolic + 1/3 (systolic minus
diastolic) BP.
Fasting blood samples (12-h fast) were collected from
an antecubital vein into evacuated tubes containing diso-
dium EDTA at the beginning and at the end of each inter-
vention period for the measurement of fasting blood
lipids. Samples were then immediately centrifuged at 4°C
for 10 min at 1500 × g to obtain plasma samples, which
were then stored at 4°C until processed. Plasma lipid
concentrations were measured as described earlier [30].
ApoB and apoA-I concentrations were measured by neph-
elometry [31]. Nondenaturing 2% to 16% polyacrylamide
gradient gel electrophoresis was used to characterized LDL
particle size using plasma stored at −80°C as described
previously [32]. Inflammatory state was assessed by plasma
C-reactive protein (CRP) and plasma adiponectin concen-
trations. CRP levels were measured by using a commer-
cially available, highly-sensitive immunoassay with a
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(Behring Latex Enhanced on the Behring Nephelometer
BN-100; Behring Diagnostic, Westwood, MA) [33] and
plasma adiponectin by commercial ELISA kit (Linco
Research Inc., St Charles, MO, USA). Endothelial function
was assessed via the surrogate markers endothelin-1, vas-
cular cell adhesion molecule 1 (VCAM-1), intercellular
adhesion molecule 1(ICAM-1) and E-selectin [34]. These
markers were measured using commercially available as-
says (R&D Systems, Inc., Minneapolis, MN, USA). Choles-
terol homeostasis was assessed also by validated plasma
surrogate markers of cholesterol absorption (β-sitosterol
and campesterol) and cholesterol endogenous synthesis
(lathosterol) as previously described [35]. Concentrations
were expressed relative to plasma total cholesterol con-
centrations (× 102 μmol/mmol of cholesterol of the same
GC run) to correct for the differing number of lipoprotein
acceptor particles [36].
A 75-g oral glucose tolerance test (OGTT) was per-
formed by each participant in the morning after an over-
night fast at the end of the two diets. Blood samples were
collected in EDTA-containing tubes (Miles Pharmaceuti-
cals, Rexdale, Ontario, Canada) through a venous catheter
placed in an antecubital vein at −15, 0, 15, 30, 45, 60, 90,
120, 150, and 180 minutes at the end of each diets for
the measurement of plasma glucose and insulin concen-
trations. Plasma glucose was measured enzymatically [37],
whereas plasma insulin was measured by radioimmuno-
assay with polyethylene glycol separation [38]. The glucose
and insulin areas under the curve (AUC) were calculated
after the 180 minutes OGTT using the trapezoid method.
The HOMA [39], Cederholm [40] and Matsuda [41]
insulin sensitivity indices were calculated from the OGTT
glucose and insulin data.VLDLapoB and ApoA-I kinetics
VLDLapoB and apoA-I kinetics were investigated at
the end of the MILK diet and the NCEP diet in nine
(n = 9) women in the constantly fed state using a
primed constant infusion of [5,5,5-2H3]-L-leucine, as
described previously [42]. VLDLapoB (d < 1.006 g/ml)
and apoA-I (d < 1.25 g/mL) at various time points dur-
ing the infusion were individually isolated from whole
plasma by ultracentrifugation as described previously
[43,44]. Fractional catabolic rate (FCR) of VLDLapoB and
apoA-I were individually determined by fitting the isotopic
ratios over time to monoexponential functions, using the
SAAM II software (University of Washington, Depart-
ment of Bioengineering, Seattle, WA), as described previ-
ously [42]. VLDLapoB-100 enrichment plateau was
used as the forcing function reflecting precursor pool en-
richment. Absolute production rate (PR) was calculated
(in mg/kg/d) using the formula:PR ¼ FCR pools=dayð Þ  plasma apo pool size mgð Þ
Body weight kgð Þ
Pool size was calculated as the plasma apo concentration
(mg/L) multiplied by plasma volume (value fixed at
0.045 L/kg body weight).
Sample size estimate
Previous dietary intervention studies have observed SD of
the treatment effects on lipid risk factors to range from
100% to 200% of the treatment effect per se, the largest
SD usually being related to TG levels [45]. We have shown
that the SD of the change in plasma TG levels following a
high MUFA diet consumed for 6–7 weeks under con-
trolled conditions was approximately 150% larger than the
diet-effect per se (−0.17% ± 25% mmol/l, P = 0.0064,
N = 32 men) [46]. We have performed our power calcu-
lations using a fairly conservative SD of the treatment
effect that was equivalent to 180% of the treatment ef-
fect per se. Under the above assumptions and with a
final sample size of 30, the study could detect with a
power of 83% at α = 0.05 clinically meaningful treatment
effects in any of the primary and secondary outcomes. For
example, estimates indicated that a clinically meaningful
increase in TG levels of 20% ± 36% associated with milk
consumption would be significant at P = 0.05 with a
power = 83%. Any greater treatment effect or any smaller
SD of treatment effect, the latter being likely to occur for
many of the risk variables of interest, would be measured
with greater statistical power. Based on the expected attri-
tion rate (10%), we had planned to recruit 34 women to
have a sample size of 30 available for final analyses. How-
ever, as mentioned above, we did not achieve this target.
Twenty-nine women were randomized, 27 completed the
protocol and 2 dropped-out.
Statistical analysis
Data were analyzed using mixed models for repeated
measures in SAS (version 9.2; SAS Institute Inc, Cary,
NC, USA). The primary analysis used changes (post diet
values vs. diet-specific baseline values) as the dependent
variable. Diet (MILK vs. NCEP) and sequence were
treated as fixed effects and subject was treated as ran-
dom effect. Diet-specific baseline values were included in
the mixed models as co-variables when possible (such data
were not available for surrogate markers of cholesterol
homeostasis and of endothelial function, apo A-I and apo
B kinetics and OGTT variables, which were measured
only post-intervention). As shown in the results’ section,
body weight and waist circumference decreased signifi-
cantly during both phase, with a slightly greater reduction
after the NCEP diet. Thus, change in waist circumference
with diet was included in all models as a covariate to
account for this potential confounding effect. Using
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ences as a covariate had no impact on the results (not
shown). Treatment by sequence effects were tested for
each outcome as a covariate but were included in the
final model only when significant. This was the case for
body weight, BMI, total plasma cholesterol, apo A-I,
total apo B, diastolic BP, mean BP and mean glucose
levels. Values are reported as means ± SD, unless stated
otherwise. VLDL-C and fasting insulin values were log10-
transformed prior to statistical analysis to normalize their
distribution. Three subjects were found to have CRP con-
centrations >10 mg/L at least once during the course of
the study. According to Pearson et al. [47], CRP levels >
10 mg/L reflect infection or acute inflammation. Those
individual data at this particular time point were treated
as “missing” in the mixed models for this specific risk
factor. Differences were considered significant at P < 0.05.
Results
All women were overweight or obese when screened
and had a waist circumference greater than the thresh-
old for the MetS based on the NCEP-ATP III criteria
[25] (≥88 cm) (Table 2). Based on the same criteria, low
HDL-C, high TG, high BP and high plasma glucose
concentrations were present in 63%, 46%, 89% and 13%
of the participants respectively at screening. A total of
63% women had MetS.
As shown in Table 3, consumption of the MILK diet for
6 weeks significantly reduced plasma HDL-C levels (−16.2%;
P < 0.001) but had no impact on plasma total and LDL-C
levels so that the total/HDL-C ratio was increased signifi-
cantly compared with baseline values (+15.9%; P < 0.001).
Changes in LDL-C and HDL-C after the MILK diet were
similar in magnitude to the ones seen after the control
NCEP diet (between-diet P > 0.05). On the other hand, theTable 2 Characteristics of the 27 postmenopausal women
at the screening visit
Variable Range
Age (yrs) 57±- 5 (48-66)
Body weight (kg) 83.3 ± 10.6 (68.1-110.3)
Waist circumference (cm) 99.1 ± 7.3 (89.0-116.0)
Body mass index (kg/m2) 31.9 ± 3.5 (26.2-39.0)
Total cholesterol (mmol/L) 5.9 ± 1.0 (4.1-7.9)
LDL-cholesterol (mmol/L) 3.73 ± 0.84 (2.2-5.4)
HDL-cholesterol (mmol/L) 1.33 ± 0.25 (1.0-2.1)
Triacylglycerol (mmol/L) 1.82 ± 0.74 (0.9-2.6)
Systolic blood pressure (mmHg) 118.8 ± 13.5 (96.0-150.0)
Diastolic blood pressure (mmHg) 73.5 ± 6.9 (61.0-90.7)
Fasting glucose (mmol/L) 5.59 ± 0.46 (4.8-6.7)
% with metabolic syndrome 63%
Values are shown as mean ± SD.reduction in total plasma cholesterol concentrations
was statistically more important after the NCEP diet than
after the MILK diet (between-diet P = 0.01). Therefore,
the total/HDL-C ratio increased in a similar extend during
both phases (between-diet P = 0.26). Plasma levels of ste-
rols (sum of beta-sitosterol and campesterol) were signifi-
cantly lower at the end of the MILK diet than after the
NCEP diet (−12.0%, P = 0.04, Figure 1) while no difference
was seen between diets in plasma lathosterol concentrations.
The reduction in plasma apo A-I concentrations after
consumption of the MILK diet for 6 weeks (−7.9%,
P < 0.001) compared to baseline values tended to be
smaller than the reduction seen after NCEP (−12.1%,
within-diet P < 0.001, between-diet P = 0.06). This dif-
ference could not be ascribed to differences in apo A-I
PR or FCR between diets (Table 4). Neither the control
NCEP nor the MILK diets had an impact on plasma
total VLDL-C, VLDL-TG or VLDL-apoB concentra-
tions, although there was a significant reduction in
VLDL apoB FCR after the MILK diet compared with
the NCEP diet (−13.4%; P = 0.04; Table 4). Neither the
MILK nor the NCEP diets had an impact on measures
of LDL particle size.
While there was no effect of the MILK and NCEP regi-
mens on plasma CRP, both treatments reduced plasma
adiponectin in a similar way (−11.1% and −13.3% respect-
ively, between-diet P = 0.58). MILK significantly reduced
systolic (−4.1%) and diastolic (−5.2%) BP compared with
baseline values (Figure 2). Although smaller in magnitude
and not significant after the NCEP diet, reductions in sys-
tolic and diastolic BP were comparable between the two
treatments. The reduction in mean BP with MILK (−4.7%,
P < 0.05) tended to be greater than after the NCEP diet
(−1.1%, NCEP within-diet P > 0.05, between-diet P = 0.07).
Plasma endothelin concentrations decrease significantly and
similarly during both treatments (between-diet P = 0.85).
Post diet levels of VCAM-1, ICAM-1 and E-selectin were
similar between MILK and NCEP (Table 3).
Finally, both the MILK and NCEP diets similarly re-
duced plasma fasting glucose levels compared with diet-
specific baseline values (between-diet P = 0.22, Table 5).
There was no significant difference in any other markers
of glucose homeostasis or any insulin sensitivity indices
between treatments.
Discussion
A systematic review published in 2011 concluded that
the majority of available epidemiological studies suggest
potential benefits of dairy consumption on the risk of
having or developing MetS [48]. However, the authors
have highlighted important methodological heterogeneity
between studies and potential biases that prevent firm
conclusions to be drawn. They have also emphasized on
the importance of undertaking high quality randomized
Table 3 Comparisons of the effects of the MILK and NCEP diets on the different cardiometabolic risk factors
Variables MILK NCEP P between
Pre Post % P within Pre Post % P within
Body weight (kg) 82.6 ± 10.3 81.9 ± 10.4 −0.8% 0.003 82.8 ± 10.5 81.5 ± 10.4 −1.6% <0.001 0.007
Waist circumference (cm) 102.7 ± 8.4 102.8 ± 7.9 0.1% 0.92 104.0 ± 9.0 101.8 ± 8.3 −2.1% 0.004 0.03
Body mass index (kg/m2) 31.7 ± 3.3 31.4 ± 3.4 −0.8% 0.001 31.7 ± 3.5 31.2 ± 3.4 −1.6% <0.001 0.007
Total cholesterol (mmol/L) 5.75 ± 0.84 5.60 ± 0.87 −2.6% 0.39 5.87 ± 0.78 5.53 ± 0.76 −5.8% <0.001 0.01
VLDL cholesterol (mmol/L)a 0.55 ± 0.48 0.58 ± 0.43 5.3% 0.78 0.51 ± 0.32 0.47 ± 0.37 −7.9% 0.64 0.57
LDL cholesterol (mmol/L) 3.94 ± 0.55 3.97 ± 0.78 0.8% 0.96 4.11 ± 0.71 3.98 ± 0.71 −3.0% 0.36 0.42
HDL cholesterol (mmol/L) 1.27 ± 0.25 1.06 ± 0.19 −16.2% <0.001 1.26 ± 0.20 1.08 ± 0.19 −14.1% <0.001 0.29
Total/HDL cholesterol ratio 4.68 ± 1.10 5.42 ± 1.23 15.9% <0.001 4.81 ± 1.12 5.28 ± 1.24 9.9% <0.001 0.26
Triglycerides (mmol/L)a 1.84 ± 0.86 1.87 ± 0.92 1.9% 0.77 1.78 ± 0.75 1.60 ± 0.78 −10.2% 0.14 0.14
VLDL triglycerides (mmol/L)a 1.35 ± 0.78 1.40 ± 0.85 3.5% 0.64 1.29 ± 0.69 1.16 ± 0.73 −9.8% 0.25 0.18
LDL size (Å) 256.4 ± 2.8 256.3 ± 2.4 0.0% 0.64 256.1 ± 2.9 256.2 ± 2.6 0.0% 0.74 0.59
LDL-PPD (Å) 255.6 ± 2.9 255.3 ± 2.7 −0.1% 0.45 255.2 ± 3.0 255.5 ± 3.0 0.1% 0.59 0.27
Apo A-I (g/L) 1.52 ± 0.18 1.40 ± 0.16 −7.9% <0.001 1.55 ± 0.17 1.36 ± 0.18 −12.1% <0.001 0.06
Apo B (g/L) 1.11 ± 0.21 1.10 ± 0.22 −1.6% 0.29 1.13 ± 0.19 1.07 ± 0.18 −4.8% 0.02 0.37
VLDL apo B (g/L) 0.16 ± 0.08 0.16 ± 0.08 −0.5% 0.94 0.14 ± 0.06 0.13 ± 0.07 −7.2% 0.36 0.42
LDL apo B (g/L) 0.96 ± 0.15 0.94 ± 0.19 −1.8% 0.32 0.98 ± 0.17 0.94 ± 0.15 −4.4% 0.06 0.53
CRP (mg/L) 2.94 ± 1.80 3.19 ± 2.30 8.5% 0.40 3.38 ± 2.49 3.09 ± 2.33 −8.8% 0.21 0.15
Adiponectine (mmol/L) 10.52 ± 4.31 9.36 ± 4.26 −11.1% 0.01 10.80 ± 4.47 9.36 ± 4.09 −13.3% 0.001 0.58
Endothelin (pg/mL) 0.65 ± 0.25 0.57 ± 0.30 −11.5% 0.003 0.66 ± 0.35 0.55 ± 0.23 −17.6% 0.001 0.85
VCAM-1 (ng/mL) nd 655.2 ± 179.4 nd 690.7 ± 184.5 −5.1% 0.25
ICAM-1 (ng/mL) nd 203.8 ± 48.8 nd 193.9 ± 32.6 5.1% 0.22
E-selectin (ng/mL) nd 32.8 ± 15.3 nd 30.5 ± 12.3 7.5% 0.51
Values are shown as mean ± SD.
aValues were log-transformed before statistical analyses.
Diet specific baseline values and changes in waist circumference were included as covariates in all models, except when outcomes were measured only post diet,
in which case post diet waist circumference was included as a covariate. Change in waist circumference was also not included as a covariate when analysing this
particular outcome. PPD: peak particle diameter, Apo: apolipoprotein, CRP: C-reactive protein, VCAM-1: vascular cell adhesion molecule 1, ICAM-1: Intercellular
adhesion molecule 1, nd: not determined.
Figure 1 Percent difference between diets in surrogate markers
of cholesterol homeostasis. *: Significant change, P < 0.05. Values
are mean ± SEM. Differences between dietary phases were tested by
the MIXED procedure for repeated measurements using post diet
values as the dependent variable, with adjustment for post diet
waist circumference. Similar results were obtained when values were
reported as ratios to plasma cholesterol (not shown).
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foods on cardiometabolic risk.
According to the recent meta-analysis of 20 randomized
controlled studies by Benatar et al. [49], consumption of
either high fat or low fat dairy has no impact on LDL-C,
HDL-C, CRP, and on systolic and diastolic BP. The aver-
age difference in dairy intake between the dairy and con-
trol groups or treatments in these studies approximated 3
serving sizes /d. In these studies, the majority of partici-
pants (78%) were female, mean age was 51 ± 16 years and
median duration of follow up was 26 weeks. Fifteen studies
had a parallel group design and 5 were crossover studies.
Only 1 of the 20 studies was a fully controlled feeding study
and 4 were in postmenopausal women specifically. Authors
have characterized most studies as being of moderate
quality. The present study was carefully controlled and
results are quite consistent with data from this meta-
analysis. Indeed, we have shown that consumption of
approximately 3 servings/day (3.2 servings/2000 kcal)
of partly skimmed 2% fat milk in the context of an
Table 4 VLDL apoB and apoA-I kinetic data in a sub-
sample of nine (n = 9) postmenopausal women after the
MILK and NCEP diets
Variables MILK NCEP % P
Apo A-I
Pool size (mg) 5282 ± 892 4771 ± 885 10.7% 0.25
Production
rate (mg/kg/d)
19.1 ± 3.1 17.6 ± 6.5 8.5 0.73
Fractional catabolic
rate (pools/d)
0.29 ± 0.05 0.29 ± 0.09 1.3% 0.87
VLDL apoB
Pool size (mg) 681 ± 287 605 ± 242 12.7% 0.08
Production
rate (mg/kg/d)
36.0 ± 14.7 37.6 ± 13.5 −4.4% 0.45
Fractional catabolic
rate (pools/d)
4.74 ± 1.81 5.47 ± 1.84 −13.4% 0.04
Values are mean ± SD.
Apo: apolipoprotein.
Differences between diets were tested using MIXED models for repeated
measurements, while including waist circumference (post diet values) as
a covariate.
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http://www.nutritionj.com/content/14/1/12NCEP prudent diet has essentially no positive or negative
impact on a wide spectrum of cardiometabolic features as-
sociated with MetS in postmenopausal women with ab-
dominal obesity. On the other hand, our data and those
from Benetar et al. [49] are mostly inconsistent with data
from epidemiological studies, which have shown favorable
relationships between milk intake and plasma HDL-C and
TG concentrations [12,50]. Such inconsistencies may be
due to many factors, including important differences in
the nutrient content of milk and dairy products investi-
gated in these studies, but also more simply on inherentFigure 2 Changes from baseline in systolic, diastolic and mean
blood pressure (BP) after the MILK and the control NCEP diets.
Within and between-diet differences were tested by the MIXED
procedure for repeated measurements using the change in blood
pressures from baseline as dependent variables. *: Significant
within-diet change (change from baseline, P < 0.05). Values are
mean ± SEM. Diet-specific baseline values and changes in waist
circumference were included as covariates in the models.differences in study design and analyses between clinical
trials and observational studies [51].
Data from randomized clinical studies meta-analysed in
[49] indicated that intake of high fat dairy, not low fat
dairy, increases plasma glucose concentrations. This appar-
ent hyperglycemic effect of high fat dairy was largely attrib-
uted to one specific study, which accounted for 50% of the
sample size in the analysis. The HOMA insulin sensitivity
index was unchanged after dairy consumption (low and
high fat not specified), although it is stressed that this
assessment is based on only 4 studies [49]. In our study,
consumption of 2% fat milk for 6 weeks in the context of a
prudent diet reduced plasma glucose concentrations, but
this was not more important than the reduction seen with
the NCEP prudent diet alone. The impact of the 2 diets on
plasma insulin levels and on the HOMA insulin sensitivity
index was also very similar. In contrast with these data
from clinical studies, consumption of total dairy and cheese,
but not milk, has been associated in epidemiological studies
with a reduced risk of type 2 diabetes [16-18]. This is in
part consistent with results on glucose homeostasis from
the present trial. However, the shorter term of clinical stud-
ies may not be sufficient to yield full beneficial effects of
dairy products other than milk on glucose homeostasis and
subsequently on the risk for type 2 diabetes. It is also pos-
sible that residual confounding associated with milk and
dairy intake in epidemiological studies may result in favor-
able associations with type 2 diabetes. This apparent
disconnect between clinical and epidemiological data
needs further investigation.
Interestingly, plasma adiponectin levels decreased dur-
ing both the MILK and the NCEP diets. Based on existing
data [52], reductions in total fat and saturated fat intakes
compared with usual intakes should have led to increased
plasma adiponectin levels. Forbidding alcohol consump-
tion during the MILK and NCEP diets may explain to
some extent the reduction in adiponectin compared with
baseline values. Indeed, moderate alcohol drinking had
been associated with elevations in adiponectin levels [52].
The reduction in plasma HDL-C and apo A-I after both
diets may also be attributable in part to the restricted alco-
hol consumption [53] as well as to reduced saturated fat
intake [54] during the feeding phases compared with the
participants’ usual diets. The kinetic sub-studies did not
allow us to identify the exact mechanisms through which
HDL-C and apo A-I were modified by milk consumption,
nor why the reduction in plasma apo A-I tended to be
smaller with the MILK diet compared with the control
NCEP diet. Finally, there was no effect of milk consumption
on plasma CRP concentrations in these postmenopausal
women. Data from a recent systematic review by our group
has shown that the impact of dairy on inflammation is
not yet well characterized with inconsistent results
between RCT [55].
Table 5 Comparisons of the effects of the MILK and NCEP diets of indices of insulin and glucose homeostasis
Variables MILK NCEP P between
Pre Post % P within Pre Post % P within
Fasting glucose (mmol/L) 6.08 ± 0.39 5.77 ± 0.45 −5.1% <0.001 5.98 ± 0.47 5.80 ± 0.53 -3.1% 0.009 0.22
Fasting insulin (mmol/L) 160.0 ± 93.5 159.9 ± 81.3 0.0% 0.96 166.6 ± 113.8 148.2 ± 91.2 −11.0% 0.11 0.09
Glucose AUC (mmol/L/min) nd 1415 ± 57 nd 1437 ± 381 −1.5% 0.29
Insulin AUC x105 (mmol/L/min) nd 1.96 ± 1.60 nd 2.03 ± 1.74 −3.3% 0.85
ISI Cederholm nd 11.9 ± 4.0 nd 11.8 ± 4.6 0.3% 0.68
ISI Matsuda nd 5.16 ± 2.66 nd 5.55 ± 3.49 −7.0% 0.31
Values are mean ± SD, N = 25 for all variables.
Differences between diets were tested using MIXED models for repeated measurements.
Diet specific baseline values and changes in waist circumference were included as covariates in all models, except when outcomes were measured only post diet,
in which case post diet waist circumference was included as a covariate.
AUC: area under the curve, ISI: Insulin sensitivity index.
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tion studies [15], each 200 g/d serving of milk is associated
with a small but significant 4% reduction in the risk of
hypertension. Consistent with these data, we have shown
that 6-week consumption of 2% milk significantly reduced
systolic, diastolic and mean blood pressure compared with
baseline in postmenopausal women, who had in average
relatively normal usual BP levels. However, only the reduc-
tion in mean blood pressure tended to be greater during
the MILK diet compared with the control NCEP diet.
Studies have suggested that certain peptides derived from
milk proteins may modulate endothelin-1 release by endo-
thelial cells, thereby partly explaining the anti-hypertensive
effect of milk proteins [56]. Our data suggest that this path-
way is probably not involved in the present case since the
changes in plasma endothelin-1 concentrations were
comparable between the 2 diets.
This study investigated the impact of milk consumption
in the context of a prudent NCEP diet on a comprehensive
list of cardiometabolic risk factors. Unlike previous studies
that have combined various dairy products, results from
the present study can be ascribed only to milk. Indeed, milk
was replaced in the control diet by specific nutrients and
not with control foods that might have confounding effects
on their own. Although not conclusive, the study examined
potential mechanisms underlying the changes in plasma
lipids using surrogate markers of cholesterol metabolism
and VLDL and HDL kinetics. The relatively small sample
size may have limited our ability to detect changes in car-
diometabolic risk factors. Studies have shown that periods
as short as three days were sufficient to induce significant
changes in cardiometabolic risk factors including plasma
TG, LDL-C and small dense LDL [57]. We have also shown
recently that blood pressure was modified after a 4-week
period of a dairy rich diet in a partly controlled feeding
context [58]. Nevertheless, we recognize that testing
the impact of milk consumption over a longer period
may amplify some of the minor changes seen in the
present study.Conclusions
Data from this controlled-feeding study indicated that
short-term consumption of 2% fat milk in the context of a
low fat prudent diet has limited effects on a wide spectrum
of cardiometabolic risk factors associated with MetS in
postmenopausal women with abdominal obesity. Further
studies are needed to explain why milk or dairy consump-
tion in epidemiological studies is generally associated with
reduced risk of MetS, CHD and type 2 diabetes.
Additional file
Additional file 1: Table S1. Typical one day menu on the MILK and the
NCEP milk-free diets.
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